# Table of Contents

Sincerely, Leadership ............................................................... 3  
Our Mission ............................................................................. 4  
Our Impact .............................................................................. 5  
Fighting for Research Dollars and Access to Health Care ........ 6  
Empowering People with ALS to Live Their Best Lives .......... 7  
Searching for Better Treatments and a Cure ......................... 8  
Growing Support for the Fight ............................................... 10  
Corporate Partners ................................................................. 11  
Board of Trustees ................................................................... 12  
Financial Summary ............................................................... 13
Doing whatever it takes to attain an audacious goal requires bold, transformative action and the collective effort and singular focus of one team working together to achieve one goal. This year, we made a promise to our community to transform ALS into a livable disease. That means people diagnosed with ALS live longer lives and that they are empowered to live life as they want—with greater engagement and autotomy. It also means we are finding ways to prevent our loved ones from getting the disease. It means doing whatever it takes to find new treatments and cures, to optimize current treatments and care and making sure everyone has access to the care and assistive technology they need, regardless of where they live.

We can only make good on that commitment by marshalling all the resources available to us and aligning behind a single mission, as one team. That is why we made the decision this year to create a unified structure for our organization, which will enhance the depth and breadth of the care we provide and increase the resources available to optimize that care for people living with ALS all across the country. While it is important that as we go through the process of becoming one team with one mission, our highest priority remains our work supporting people with ALS and their families.

Sincerely,
Leadership

“This is what it takes. We are stronger as one—One team. One mission. One world without ALS.”

Calaneet Balas
President & CEO

Sue Gorman
Association Chair

Our Mission
To discover treatments and a cure for ALS, and to serve, advocate for, and empower people affected by ALS to live their lives to the fullest.

Our Vision
Create a world without ALS.

Core Values
COMPASSION - INTEGRITY - URGENCY
This year we launched a strategic goal of making ALS a livable disease and made the commitment to do Whatever it Takes to achieve that goal and fundamentally transform the lives of people living with the disease.

**Our goal: Make ALS a livable disease.**

**What This Means**

**Longer Lives**
- Life-extending treatments made accessible to ALL people with ALS
- Prevention of harms associated with ALS

**Improved Quality of Life**
- People with ALS empowered to live their lives as they want
- Greater engagement and autonomy
- Reduced or prevented physical, emotional and financial burdens

**Preventing Loved Ones from Getting ALS**
- Genetic screening to identify those at risk
- Prevention of new cases of ALS

**How We Get There**

**Find New Treatments & Cures**
- More clinical trials and participation with research
- More focused research

**Optimize Current Treatments & Care**
- Improve and deliver state of the art care
- Improve assistive technology

**Prevent or Delay Harms Associated with ALS**
- Identify risk factors
- Treat as early as possible
- Discover new preventative treatments
**Our Impact**

**ADVOCACY**

- Mobilized ALS advocates and Congress to pass the ACT for ALS Act to speed the discovery of new treatments for people living with ALS through more clinical trials and expanded access to investigational drugs.

- Galvanized ALS advocates to push for increased federal dollars for ALS research at the Department of Defense, new funding for clinical trials at FDA, and continued funding for the National ALS Registry.

- Advocated to boost funding for the National Institutes of Health, resulting in an estimated **$115 million in funding for ALS research** in fiscal year 2022.

- Preserved protections for pre-existing conditions for people living with ALS in collaboration with other leading patient advocacy groups.

**CARE SERVICES**

- 21,645 people living with ALS served through the chapter network.

- 8,515 people viewed, downloaded, or ordered our educational materials including the Living with ALS and Families and ALS resource guides and medical information packets.

- 2,081 veterans received assistance through our nationwide care network.

- 9,586 people registered with our nationwide care network and served through our Certified Treatment Centers of Excellence & Recognized Treatment Centers.

- $4,831,102 in grants provided to our Certified and Recognized Treatment Centers to support clinic operations including equipment, staffing and continuing education.

- $500K in higher educational scholarships was awarded to 100 students through the Jane Calmes Scholarship Fund.
This past year, we empowered advocates across the country to send more than 41,000 messages to members of Congress and hold more than 530 meetings with lawmakers in pursuit of public policies that will speed up the search for treatments and a cure, optimize the care available today and enhance the lives of people living with ALS.

We led a campaign to encourage the FDA to act with urgency and flexibility to make AMX0035 (now known as RELYVRIO) available for people living with ALS. In May, we convened a meeting between the agency and people living with ALS to deliver the message that We Can’t Wait for additional clinical trials when the evidence already demonstrated the therapy to be safe and effective. And when Amylyx filed its new drug application for approval, we swiftly called on the agency to conduct a priority review.

We also led the successful fight for enactment of the ACT for ALS, legislation that supports access to experimental treatments and provides the FDA additional research capacity and public/private partnerships to speed development and approval of new treatments.

In addition, we fought to preserve protections for pre-existing conditions for people living with ALS in collaboration with other leading patient advocacy groups. Urged governors to support people living with ALS and their families with access to care through telehealth and COVID-19 vaccine prioritization. Advocated to boost funding for the National Institutes of Health, resulting in an estimated $115 million in funding for ALS research in fiscal year 2022. And galvanized ALS advocates to push for increased federal dollars for ALS research at the Department of Defense, new funding for clinical trials at FDA, and continued funding for the National ALS Registry.
Empowering people with ALS to live their best lives

This past year our care services teams in communities throughout the country served more than **21,000** people living with ALS, including more than **2,000 veterans**.

We provided **$4.8 million** to our nationwide network or Certified Treatment Centers of Excellence and Recognized Treatment Centers, providing care shown to extend and enhance the quality of life to **9,586** people living with ALS.

As part of our effort to expand access to multidisciplinary ALS care, we teamed up with the Veterans Administration to increase the number of Veterans Health Administration clinics designated as Certified Treatment Centers of Excellence or Recognized Treatment Centers to make sure health care professionals are providing the best possible care available, we provided 12 online, on-demand, education webinars for professionals interested in learning more about ALS treatment and care.

All were offered **free of charge** and approved for continuing education credits for nurses, social workers and allied health professionals.

We also conducted three new **ALS Focus** surveys covering caregiver needs, telehealth and mobility challenges to learn directly from the community what their needs are and how to tailor programs and services to be responsive to those needs in real time. There are already more than **2,200** members participating in ALS Focus.

Through the **Jane Calmes ALS Scholarship Fund**, which was established in 2019 to provide $5,000 for students directly impacted by ALS, the Association awarded **100** scholarships for the 2021-2022 school year totaling **$500,000**. Since its inception, this scholarship program has awarded 239 scholarships equaling **$1,195,000**.
The ALS Association committed funding for 28 new projects around the world, with a total commitment of $9.5 million. Including previous commitments, the Association provided $10.1 million to 72 projects during the fiscal year.

When our commitment to research leads to promising new treatments, we immediately begin the work of making those treatments available to the community. Throughout the year, we worked tirelessly to bring AMX0035 (now known as RELYVRI0), a promising new drug shown to extend life and slow disease progression, to people living with ALS. The FDA recently approved Amylyx’s New Drug Application for the treatment, and we continue to push to make RELYVRI0 available for the ALS community.

**Healey platform trial progresses at super speed**
We committed $3M to co-fund the first ever platform trial in ALS. Enrollment has progressed 3 times faster than normal and is now complete for the first 4 investigational treatments with first data expected in mid-2022.

**Reducing time to diagnosis is key to ALS**
We created a new diagnostic guide, thinkALS, that will help neurologist more quickly diagnose ALS. Earlier diagnosis allows people with ALS to participate in clinical trials and access treatments sooner, as well as receive care services support. Check out this new tool at www.als.org/thinkals.

**Bringing effective treatments closer to approval**
Including RELYVRI0 from Amylyx Pharmaceuticals that was shown to extend life and slow disease progression, and continued progress on tofersen, a genetic therapy for SOD1-ALS in late phase trials, along with progress on biomarker research.

**Finding out what matters most to people with ALS and their caregivers**
Since launching, over 2,100 are members in ALS Focus. These surveys bring the perspectives and needs of people with ALS and caregivers to the forefront of program and policy decision making. To join, visit www.als.org/research/als-focus.
$9.5M spent to fund 28 new projects around the world

Other promising developments from research we supported include:

- Identifying the first compound (NU-9) that eliminates the ongoing degeneration of diseased upper motor neurons, a key contributor to ALS.

- The announcement by Ionis Pharmaceuticals of FUSION, of a Phase 3 clinical trial of ION363 (also known as jacifusen), a novel antisense oligonucleotide (ASO) for ALS patients with a mutation in the fused in sarcoma (FUS) gene.

- We launched a new grant funding program to support early-stage clinical trials. In addition, our Milton Safenowitz Postdoctoral Fellowship Program welcomed 4 new fellows to the only program of its kind, specifically funding early ALS postdoctoral fellows who are working eagerly to understand the disease biology and searching for a cure. Our Lawrence & Isabel Barnett Drug Development Program awarded close to $3 million to 6 projects to invest in bringing potential treatments into clinical trials.

In addition, we created new resources to help speed up the time to diagnosis and to expand the drug development pipeline.

- We launched thinkALS, an early diagnosis guide targeting general neurologists to help them easily identify ALS symptoms and refer their patients to multidisciplinary ALS centers as quickly as possible.

- We also launched a genetic counseling and genetic testing education campaign to inform people with ALS and their families about the benefits and costs of genetic testing. In order for people living with ALS and their families to make informed decisions about genetic testing, they must have access to current education about clinical genetics in ALS and safeguards against genetic discrimination.
Growing Support for the Fight

169 Walk to Defeat ALS® events held across the country, raising $19.6M

60 Golf, Gala, and CEO Soak events hosted, raising $6.7M

31 Team Challenge ALS endurance events held, raising $2.6M
The ALS Association appreciates the generosity of the many national partners we work with, and we are delighted to recognize them for their support of our research, services, and advocacy efforts this year. We appreciate your continued work to help move our mission forward in the fight against ALS.

$250K+ Partners:

MITSUBISHI TANABE PHARMA AMERICA
Mitsubishi Tanabe Pharma America became a national corporate partner in 2016 with a premier sponsorship of the Walk to Defeat ALS® program, providing support towards cutting-edge research, nationwide advocacy efforts, and care service programs for people with ALS and their families. Contributing over $3 million, they continue to support the mission through additional funding for national programs. In addition, they continue to fund the Mitsubishi Tanabe Pharma Care Grant established in 2018 enabling the Association to award grants for the expansion and implementation of new and current care services programs.

BIOGEN PHARMACEUTICALS
Biogen is a multinational biotechnology company specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Their participation as a partner has enabled additional support in ALS advocacy and understanding how to better serve the ALS community. Thanks to their over $1M investment in Association programs since 2013 Biogen has helped us expand our mission programs.

$100K+ Partners:

IONIS
numotion Foundation
permobil FOUNDATION
Board of Trustees

We are proud to acknowledge the following members of the ALS National Board of Trustees:

- **Lawrence R. Barnett**
  Founding Chairman
  (deceased)

- **Sue Gorman**
  Association Chair
  Professional interior designer/principal
  Sue Gorman Interior Designs
  Charlotte, North Carolina

- **Scott Kauffman**
  Association Chair-Elect
  Chairman & CEO
  MDC Partners
  New York, New York/Palo Alto, California

- **Fred DeGrandis**
  Association Vice-Chair
  Senior Director and President
  Medic Management LLC and NorthShore Medicine
  Cleveland, Ohio

- **Connie Houston**
  Association Treasurer
  Vice President, Finance
  Team Oney
  Louisville, Kentucky

- **Keith Gary, Ph.D.**
  Association Secretary
  Retired-Vice President
  BioNexus KC
  Kansas City, MO

- **Jinsy Andrews, MD, MSc.**
  Association Trustee
  Director of Neuromuscular Clinical Trials
  Columbia University
  New York, New York

- **Millie Arnold**
  Association Trustee
  Retired Medical Manager
  Jackson, Ohio

- **Eugene Brandon, Ph.D.**
  Association Trustee
  Head of Translation, Cell & Gene Therapies
  IQVIA
  San Diego, California

- **Mark Calmes**
  Association Trustee
  Retired, Vice President, Environmental
  Archer Daniels Midland Co.
  Ellisville, Missouri

- **Tom Carroll**
  Association Trustee
  Founding Partner
  Brand Equity, LLC
  New York, New York

- **Larry Falivena**
  Association Trustee
  Retired Account Executive
  Salesforce
  Apex, North Carolina

- **Paul Ingholt, Esq.**
  Association Trustee
  Partner
  Guidehouse LLC
  Washington, District of Columbia

- **Christi L. Kolarcik, Ph.D.**
  Association Trustee
  Faculty, Research Instructor
  U of Pittsburgh School of Medicine
  Pittsburgh, Pennsylvania

- **John P. Krave, Esq.**
  Association Trustee
  Senior Counsel
  Kaiser Foundation Hospitals
  Pasadena, California

- **Nancy LeaMond**
  Association Trustee
  Chief Advocacy & Engagement Office/Executive Vice President, Community State and National Affairs
  AARP
  Washington, District of Columbia

- **Lou Libby, M.D.**
  Association Trustee
  Physician
  The Providence ALS Center
  Portland, Oregon

- **Tommy May**
  Association Trustee
  Chairman
  Simmons First Foundation
  Pine Bluff, Arkansas

- **Kenneth Menkhaus, Ph.D.**
  Association Trustee
  Professor of Political Science
  Davidson College
  Davidson, North Carolina

- **Warren Nelson**
  Association Trustee
  President and Chief Financial Officer
  JEM Restaurant Group
  Palm Harbor, Florida

- **Sandra (Sandy) Piersol**
  Association Trustee
  Corporate Compliance Officer
  McBee, division of Netsmart Tech
  Wayne, Pennsylvania

- **Charles J. Robinson, D.Sc., P.E.**
  Association Trustee
  Director, Center for Rehabilitation Engineering
  Chair Professor
  Department of Electrical Computer Engineering
  Clarkson University
  Potsdam, New York

- **John Robinson, Ed.D.**
  Association Trustee
  Retired U.S. Army
  Parrish, Florida

- **David Van de Riet**
  Association Trustee
  Vice President, Investments
  Raymond James & Associates
  St. Louis, Missouri

- **Wendy J. Schriber, Esq.**
  Association Trustee
  Retired Partner
  Proskauer Rose LLP
  New York, New York

- **Kevin Spinella, Esq.**
  Association Trustee
  Attorney
  Goodwin
  Washington, DC

- **Mark Stancil**
  Association Trustee
  Vice President
  Goldman Sachs
  Marietta, Georgia
The ALS Association continues to utilize support from our generous donors, as well as our reserves, to fulfill our mission throughout the fiscal year. The following unaudited summary reflects Association-wide financial activity for the year that ended January 31, 2021.

**Financial Summary**

**The ALS Association Home Office**

**Revenue**

- Contributions 38%
- Chapters 29%
- Bequests & Other Income 33%

**Expenses**

- Administration 10%
- Research 32%
- Fundraising 19%
- Public & Professional Education 13%

**The ALS Association Home Office and Chapters**

**Revenue**

- Total Combined Revenue $108.0M

**Expenses**

- Research $14.1M
- Other Program Activities $59.0M
- Fundraising $15.5M
- Administration $10.2M
- Total Combined Expenses $98.8M

**Assets**

- Change in Net Assets $9.2M
- Total Combined Assets $185.7M
- Total Combined Liabilities $14.0M
- Total Combined Net Assets $171.7M

FY2022 Annual Report